We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Silence Therapeutics Plc | LSE:SLN | London | Ordinary Share | GB00B9GTXM62 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 535.00 | 521.00 | 524.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
19/4/2015 12:20 | But savvy shareholders know what they are in for when they sink money into biotech. The cash calls will keep on coming, three out of four investments will fail and there will not be returns for years. Even Silence’s most advanced treatment — for pancreatic cancer — is only in early stage trials. Brokers Cannacord predict Silence will be still be making pre-tax losses of £11m in 2016. | waterloo01 | |
10/4/2015 13:38 | Still think this has a long way to go and the confidence behind us now fills me with more hope than ever of recouping some losses from years gone by! | gowboy | |
10/4/2015 12:23 | That would work for me as a LTH....... | rg710 | |
09/4/2015 18:18 | Excellent sign I'd say.......and wouldn't surprise me others wanted in and may now be quickly buying up on market. | gowboy | |
04/4/2015 06:22 | So another £40m cash injection @ only 15% less than current share price Then share price hardly flinches.... Good sign I'd say for the short term. SLN are in a very niche market that is becoming very favourable and a new world of science that SLN (et all) is still scratching the surface of. Surely one of the biggies are looking very closely at this are and SLN as a way of using there cashpiles and improving their future product lines/prospects? | pwilk47490 | |
31/3/2015 09:30 | Seems like my Ipad posts don't make it onto the boards these days. Agree with all the LT's I'm a ten year vet of this stock now, so let's be mindful of where we came from and what a lot of us have in paper loss's so far? I'd still need somewhere around 800p to break even and that's not accounting for any lost interest in the days when interest would've been paid! But I'll take a cut in my losses whatever it ends up at (as long as the therapies work for those that are suffering). Welcome back mes ami's it's been a long time. Eag | ukeagle2aus | |
24/3/2015 11:44 | Apologies for analytical form of words Waterloo !! | benson384 | |
24/3/2015 06:58 | Hard to compete with sentences like this: "I amy be wrong but patience is tittering on cliff of rich/reward versus sh.t". Rather more poetic than the news on the RNS. | waterloo01 | |
24/3/2015 04:06 | Good News about the clear dose dependent difference between treatment groups for AUT027. Although it is strange that they did not give PFS for gemcitabine only. If the phase II goes well (and this update suggest that) silence will use the data to team up with big pharma for the phase III in the largely non-treatable pancreatic cancer market. Which would mean a large upfront payment and milestone and royalties payments. I can also see Alnylam Pharmaceuticals having to get a license for all of their products with silence due to patent infringement. Or perhaps it is cheaper for them in the long run to buy silence? | johnsmith321 | |
23/3/2015 21:24 | Waterloo........SLN won courtcase in Europe re-patent challenged by Alnylam (?). They thought ir worth challenging along with 3 other co's and lost. The amount of money they have and their market Cap circa $8-10bn why not just buy SLN.....? For years I have heard that SLN's tecnology/delivery is way ahead of Yanks so why not just now buy it........? Victor Kiam style !!!! Waterloo, I think you ben about a long time so your memory may pick up points I am raising and agree.........who cares all we want is a share price that now reflects the progress that has been made and the future progress............ No knowledge other than published and kept eye on this outfit for many years, I amy be wrong but patience is tittering on cliff of rich/reward versus sh.t...... Very open to critiscm by all, re my thoughts. | benson384 | |
23/3/2015 17:55 | benson, where on earth did you pick that up from? Certainly not in the RNS. | waterloo01 | |
23/3/2015 16:28 | OLD usernames coming back..good to see we still all alive.....I tend to agree the good news is a suitor i.e. SLN attracting a bride with a dowry......for a marriage at a big margin ?? any other ideas anyone.............. | benson384 | |
23/3/2015 16:06 | The old SR Pharma used to trade a lot higher and post the 50-1 consolidation this trade by Mr Ross would be equivalent to £37.50 per share for the now 2000 SLN shares! It did get very hyped way too soon but it does like the potential is now slowly coming to commercialisation | lbo | |
23/3/2015 15:58 | "these results show a clear signal which requires further investigation" not a term I've heard before "signal". Given AUT027 was the BIG hope, I'm at a loss to know if this is bad news couched as good or good news with caveats. I no longer hold so don't follow that closely. | waterloo01 | |
23/3/2015 15:51 | Hmmm - I seem to recall that I bought most of mine at considerably higher than 6p pre-consolidation. Long way to go before I see a profit I suspect. | husbod | |
23/3/2015 15:39 | I must admit that the RNS this morning felt a little like an advert to potential buyers. | stuart14 | |
23/3/2015 14:59 | Consolidation I think was 50-1, so at £3 equates to 6p old money..... | benson384 | |
23/3/2015 14:35 | Cheers benson - I'm going to have to check my holding as I had shedloads initially but I cant remember what I ended up with after the consolidation. I totally agree that we should reap the benefits of the long road of research ourselves rather than be taken out on the cheap at this stage by a competitor. Fingers crossed that our patience will be well rewarded | husbod | |
23/3/2015 13:23 | Hi, Husbod, been in this for getting on 10 years, in old SR Pharma !!!!! Keep the faith sort of thing. After having won court case re-patent against Anylam et all this is great news, but also may imply that all along SLN technology far better than the yanks (market Cap $10bn) or whatever........exci | benson384 | |
23/3/2015 13:05 | Haven't been on here for a couple of years at which time I had more or less decided my share certificates would make good wall-paper and just about nothing else. So I half expected to see all the old timers in a state of near ecstacy with today's rise but it looks as if everyone has sold out or died. Wonder what the potential here is if everything goes according to plan - I only ask as I have almost completely forgotten why I invested here in the first place apart from the fact that the company seemed to be potentially in the forefront of some revolutionary cancer treatment procedures. Mr West Wales - are you still around? | husbod | |
23/3/2015 11:54 | Can't believe that SARS isn't soaring with the effect the rise in this, their largest holding by far, will have on SARS NAV. | callumross | |
23/3/2015 11:19 | i cant believe that nobody has posted any comment on this mornings rns and buying . | partner | |
20/2/2015 09:59 | It is finally looking like a sustained rise. Just too much good license/patent news to ignore? All looking good with the trials? Fingers crossed!! | pwilk47490 | |
19/2/2015 13:39 | Wonder if it will go all the way back to the top :-) | barefoot1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions